Press release
Methylmalonic acidaemia Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight
Methylmalonic acidaemia Pipeline
Methylmalonic acidemia refers to a group of inherited conditions in which the body can't breakdown certain parts of proteins and fats. This leads to a build-up of toxic substances and bouts of serious illness called decompensation events or metabolic crises. Symptoms of a decompensation event include poor feeding, vomiting, trouble breathing, and lack of energy (lethargy). These can occur at different ages and can range from mild to severe.
"Methylmalonic acidaemia Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Methylmalonic acidaemia Market.
The Methylmalonic acidaemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
To know more about the Methylmalonic acidaemia Pipeline Insight, click here: https://www.delveinsight.com/report-store/methylmalonic-acidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's Methylmalonic acidaemia Report covers around 8+ products under different phases of clinical development like
• Late-stage Methylmalonic acidaemia products (Phase III)
• Mid-stage Methylmalonic acidaemia products (Phase II)
• Early-stage Methylmalonic acidaemia product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Methylmalonic acidaemia Route of Administration
Emerging Methylmalonic acidaemia Drugs Under Different Phases of Clinical Development Include:
• HST5040: HemoShear Therapeutics
• LB-001: LogicBio Therapeutics
And Many Others.
Further Methylmalonic acidaemia product details are provided in the report. Download the Methylmalonic acidaemia pipeline report to learn more about the emerging Methylmalonic acidaemia therapies at: https://www.delveinsight.com/sample-request/methylmalonic-acidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Methylmalonic Acidaemia Pipeline Analysis
The Methylmalonic acidaemia report provides insights into:
The report provides detailed insights about companies that are developing therapies for the treatment of Methylmalonic acidaemia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Methylmalonic acidaemia Treatment.
Methylmalonic acidaemia key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Methylmalonic acidaemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Methylmalonic Acidaemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF Report for Methylmalonic acidaemia pipeline assessment- https://www.delveinsight.com/sample-request/methylmalonic-acidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key companies in the Methylmalonic acidaemia Therapeutics Market:
Some of the Methylmalonic acidaemia companies working in the market are HemoShear Therapeutics, LogicBio Therapeutics, Moderna Therapeutics, Selecta Biosciences, PTC Therapeutics, Poseida Therapeutics, CoA Therapeutics, Agios Pharmaceuticals and Others.
Request for Sample PDF Report to know more about Methylmalonic acidaemia therapies and drugs- https://www.delveinsight.com/sample-request/methylmalonic-acidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Methylmalonic acidaemia Current Treatment Patterns
4. Methylmalonic acidaemia - DelveInsight's Analytical Perspective
5. Methylmalonic acidaemia Therapeutic Assessment
6. Methylmalonic acidaemia Late Stage Products (Phase-III)
7. Methylmalonic acidaemia Mid-Stage Products (Phase-II)
8. Methylmalonic acidaemia Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Methylmalonic acidaemia Products
11. Dormant Methylmalonic acidaemia Products
12. Methylmalonic acidaemia Discontinued Products
13. Methylmalonic acidaemia Product Profiles
14. Key Companies in the Methylmalonic Acidaemia Market
15. Key Products in the Methylmalonic acidaemia Therapeutics Segment
16. Dormant and Discontinued Products
17. Methylmalonic acidaemia Unmet Needs
18. Methylmalonic acidaemia Future Perspectives
19. Methylmalonic acidaemia Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about recent developments in Methylmalonic acidaemia clinical trials - https://www.delveinsight.com/sample-request/methylmalonic-acidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Methylmalonic acidaemia Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight here
News-ID: 2758798 • Views: …
More Releases from DelveInsight Business Research
Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining …
DelveInsight's newly released report, "Geographic Atrophy Pipeline Insight" offers a comprehensive analysis of the evolving Geographic Atrophy (GA) therapeutic landscape, covering 23+ biopharmaceutical companies and 25 investigational drug candidates. The report features in-depth profiles of both clinical- and preclinical-stage assets, along with a detailed therapeutic assessment categorized by product type, development phase, route of administration, and molecular class. It also provides visibility into inactive and discontinued pipeline programs within the…
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies …
DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory…
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by …
DelveInsight's latest publication, "Vein Illumination Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive analysis of existing and future market dynamics. The report examines evolving trends, technological advancements, key market challenges, growth catalysts, and limiting factors, while also showcasing upcoming product launches and profiling the major players influencing the vein illumination devices industry.
Based on DelveInsight's most recent evaluation, the global vein illumination devices market is anticipated to experience…
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Fu …
DelveInsight's "Liver Cancer Pipeline Insights 2025" delivers an in-depth overview of the liver cancer pipeline ecosystem, profiling more than 70 companies and 75+ therapeutic candidates under development. The report thoroughly examines liver cancer drug profiles across both clinical and preclinical stages. It also evaluates the therapeutic landscape by product category, development phase, route of administration, and molecular class, while additionally identifying inactive and discontinued assets within the pipeline.
Stay informed with…
More Releases for Methylmalonic
2025-2034 Methylmalonic Acidemia (MMA) Market Evolution: Disruptions, Innovation …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Methylmalonic Acidemia (MMA) Market Through 2025?
The domain pertaining to methylmalonic acidemia (mma) has experienced robust expansion recently, projected to advance from a valuation of $9.39 billion in 2024 to $9.94 billion the following year, reflecting a compound annual growth rate (CAGR)…
Methylmalonic Acidemia Market trends, Diagnosis, and Treatment Landscape
Methylmalonic Acidemia (MMA) is a rare inherited metabolic disorder resulting from defects in the metabolism of certain amino acids, cholesterol, and fatty acids. It is typically caused by mutations in genes responsible for the enzyme methylmalonyl-CoA mutase or related pathways. Patients with MMA are unable to properly break down specific compounds, leading to accumulation of toxic substances in the blood, which can result in developmental delays, recurrent metabolic crises, and…
Methylmalonic Acid Market: An In-Depth Analysis
In 2024, the market was valued at approximately USD 250 million and is projected to reach around USD 400 million by 2033, reflecting a compound annual growth rate (CAGR) of 5.5% from 2025 to 2033.
Methylmalonic Acid Market Overview
Methylmalonic acid serves as a crucial biomarker in clinical settings, aiding in the diagnosis of conditions such as methylmalonic acidemia and other vitamin B12-related disorders. The market's growth is fueled by the rising…
Methylmalonic Acidemia (MMA) Market Size Projected To Reach $12.5 Billion By 203 …
The Methylmalonic Acidemia (MMA) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Methylmalonic Acidemia (MMA) Market?
The market for methylmalonic acidemia (MMA) has experienced robust growth in the past few years. The size of the market is forecasted to…
Methylmalonic Acid Market Will Generate Record Revenue by 2029
The Methylmalonic Acid Market is anticipated to grow at a significant CAGR during the forecast period. Methylmalonic acid (MMA) is a substance created by the human body when it digests protein. The amount of vitamin B12 in the body controls the production of MMA in the body. A high amount of MMA typically means a deficiency of vitamin B12.?The major factor driving the growth of the market during the forecast…
Methylmalonic Acidemia Market to Show a Rise During the Forecast Period asserts …
DelveInsight's "Methylmalonic Acidemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Methylmalonic Acidemia, historical and forecasted epidemiology as well as the Methylmalonic Acidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Methylmalonic Acidemia market report provides current treatment practices, emerging drugs, Methylmalonic Acidemia market share of the individual therapies, and current and forecasted Methylmalonic Acidemia market size…
